Identification and characterization of
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
23 Apr 2020
23 Apr 2020
Historique:
received:
24
12
2019
accepted:
30
03
2020
entrez:
2
5
2022
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Infigratinib (INF) is a novel, small molecule that is orally administered to inhibit human fibroblast growth factor receptors (FGFRs), which are a family of receptor tyrosine kinases that may be upregulated in different tumor cell types. On 6 January 2020, the FDA granted fast track designation to INF for first-line treatment of cholangiocarcinoma. Prediction of susceptible sites of metabolism and reactivity pathways (cyanide and GSH) for INF was performed by the Xenosite web predictor tool. Then, we report the characterization and identification of
Identifiants
pubmed: 35498820
doi: 10.1039/c9ra10871h
pii: c9ra10871h
pmc: PMC9052791
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16231-16244Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
RSC Adv. 2018 Jan 3;8(3):1182-1190
pubmed: 35540908
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Jpn J Clin Oncol. 2005 Feb;35(2):68-73
pubmed: 15709089
Am J Clin Oncol. 2000 Aug;23(4):425-8
pubmed: 10955877
Urology. 2007 Jan;69(1 Suppl):3-16
pubmed: 17280906
J Pharm Biomed Anal. 2018 Oct 25;160:19-30
pubmed: 30055343
J Health Econ. 2003 Mar;22(2):151-85
pubmed: 12606142
Chem Cent J. 2017 May 30;11(1):45
pubmed: 29086823
Wiley Interdiscip Rev Comput Mol Sci. 2016 Mar;6(2):147-172
pubmed: 27066112
Mol Cancer Ther. 2016 Nov;15(11):2586-2597
pubmed: 27573423
Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):23-6
pubmed: 14569844
J Chem Inf Model. 2013 Dec 23;53(12):3373-83
pubmed: 24224933
Bioinformatics. 2016 Oct 15;32(20):3183-3189
pubmed: 27324196
J Pharm Biomed Anal. 2019 Feb 5;164:659-667
pubmed: 30472584
J Clin Invest. 2016 May 2;126(5):1871-84
pubmed: 27064282
Chem Res Toxicol. 2011 May 16;24(5):744-51
pubmed: 21469730
J Clin Oncol. 2017 Jan 10;35(2):157-165
pubmed: 27870574
Curr Protoc Toxicol. 2001 Aug;Chapter 14:Unit 14.2
pubmed: 23045038
Drug Discov Today. 2009 Feb;14(3-4):120-33
pubmed: 19059358
Gut Liver. 2017 Jan 15;11(1):13-26
pubmed: 27928095
J Med Chem. 2011 Oct 27;54(20):7066-83
pubmed: 21936542
Curr Cancer Drug Targets. 2018;18(10):979-987
pubmed: 29237381
Chem Biol Interact. 2009 Apr 15;179(1):25-37
pubmed: 18848531
Ann Oncol. 2006 Jun;17 Suppl 7:vii73-7
pubmed: 16760299
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jun 1;1054:93-104
pubmed: 28433551
Bioinformatics. 2015 Apr 1;31(7):1136-7
pubmed: 25411327
Clin Adv Hematol Oncol. 2019 Nov;17(11):630-637
pubmed: 31851165
Chem Cent J. 2018 Sep 24;12(1):99
pubmed: 30251155
Anal Chim Acta. 2013 Jul 25;788:89-98
pubmed: 23845486
Chem Res Toxicol. 1996 Dec;9(8):1230-9
pubmed: 8951224
Anal Chem. 2007 Nov 1;79(21):8333-41
pubmed: 17918967
Hepatology. 2019 Mar;69(3):943-958
pubmed: 30575985
Chem Res Toxicol. 2011 Sep 19;24(9):1345-410
pubmed: 21702456
Curr Cancer Drug Targets. 2009 Aug;9(5):639-51
pubmed: 19508171
Am Soc Clin Oncol Educ Book. 2016;35:185-98
pubmed: 27249699
J Pharm Biomed Anal. 2019 Jul 15;171:132-147
pubmed: 30999224